Diesterified Derivatives of 5-Iodo-2′-Deoxyuridine as Cerebral Tumor Tracers by Rösler, Thomas W. et al.
Diesterified Derivatives of 5-Iodo-29-Deoxyuridine as
Cerebral Tumor Tracers
Thomas W. Ro¨sler1,2*, Andreas Matusch1,3, Damiano Librizzi4, Oscar Arias-Carrio´n1,5, Nils Freundlieb1,6,
Helmut Hoeffken4, Wolfgang H. Oertel1, Candan Depboylu1., Gu¨nter U. Ho¨glinger1,2,5.
1 Experimental Neurology, Department of Neurology, Philipps-University, Marburg, Germany, 2German Center for Neurodegenerative Diseases (DZNE), Munich, Germany,
3 Institute of Neuroscience and Medicine (INM-2), Research Center Ju¨lich, Ju¨lich, Germany, 4Department of Nuclear Medicine, Philipps-University, Marburg, Germany,
5Department of Neurology, Technical University, Munich, Germany, 6 Brain Imaging and Neurostimulation (BINS) Laboratory, Department of Neurology, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany
Abstract
With the aim to develop beneficial tracers for cerebral tumors, we tested two novel 5-iodo-29-deoxyuridine (IUdR)
derivatives, diesterified at the deoxyribose residue. The substances were designed to enhance the uptake into brain tumor
tissue and to prolong the availability in the organism. We synthesized carrier added 5-[125I]iodo-39,59-di-O-acetyl-29-
deoxyuridine (Ac2[
125I]IUdR), 5-[125I]iodo-39,59-di-O-pivaloyl-29-deoxyuridine (Piv2[
125I]IUdR) and their respective precursor
molecules for the first time. HPLC was used for purification and to determine the specific activities. The iodonucleoside
tracer were tested for their stability against human thymidine phosphorylase. DNA integration of each tracer was
determined in 2 glioma cell lines (Gl261, CRL2397) and in PC12 cells in vitro. In mice, we measured the relative
biodistribution and the tracer uptake in grafted brain tumors. Ac2[
125I]IUdR, Piv2[
125I]IUdR and [125I]IUdR (control) were
prepared with labeling yields of 31–47% and radiochemical purities of .99% (HPLC). Both diesterified iodonucleoside
tracers showed a nearly 100% resistance against degradation by thymidine phosphorylase. Ac2[
125I]IUdR and Piv2[
125I]IUdR
were specifically integrated into the DNA of all tested tumor cell lines but to a less extend than the control [125I]IUdR. In
mice, 24 h after i.p. injection, brain radioactivity uptakes were in the following order Piv2[
125I]IUdR.Ac2[
125I]IUdR.
[125I]IUdR. For Ac2[
125I]IUdR we detected lower amounts of radioactivities in the thyroid and stomach, suggesting a higher
stability toward deiodination. In mice bearing unilateral graft-induced brain tumors, the uptake ratios of tumor-bearing to
healthy hemisphere were 51, 68 and 6 for [125I]IUdR, Ac2[
125I]IUdR and Piv2[
125I]IUdR, respectively. Esterifications of both
deoxyribosyl hydroxyl groups of the tumor tracer IUdR lead to advantageous properties regarding uptake into brain tumor
tissue and metabolic stability.
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Introduction
The onward progress in the field of anti-tumor therapies led to
increased interest in radiodiagnostics for selecting appropriate
therapeutics and for the assessment of therapy success. [18F]fluor-
odeoxyglucose (FDG) in PET analysis is a gold standard for
detecting vital tumor tissue, however, in the brain difficulties arise
from the high physiologic uptake in healthy tissue resulting in
decreased sensitivity and localizing validity for cerebral tumors.
Beside amino acid tracers [1–3], radiolabeled DNA building
blocks, thymidine analogues in particular have been tested for
localizing brain tumors with promising results [4,5]. The fact that
DNA synthesis is an essential and extensively accomplished
process in cerebral tumors, renders labeled nucleoside analogues
promising diagnostic tools for the visualization of proliferating
tissue in imaging analysis. 39-deoxy-39-[18F]fluorothymidine
([18F]FLT) has been shown to be useful for differentiating low-
grade from high-grade gliomas in PET analysis [4]. [18F]FLT is
59-phosphorylated by thymidine kinase and accumulates intracel-
lularly, but cannot be integrated into extending DNA because of
the missing hydroxyl group in 39-position. The thymidine
analogue 5-iodo-29-deoxyuridine (IUdR), in turn, takes fully part
in DNA synthesis and is covalently incorporated in DNA [5].
IUdR was first synthesized by William Prusoff in 1959 [6] and
tested as a radioiodinated tracer for DNA metabolism by Hughes
et al. in 1964 who found IUdR to be a sensitive and specific tracer
of DNA metabolism in vivo [7]. 5-[124I]iodo-29-deoxyuridine
([124I]IUdR) was the first isotopologue tested in a human study
[5]. The capacities of IUdR as mentioned above allow a narrow
correlation of tracer uptake and DNA synthesis rate on the one
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hand and a good wash out of excessive unbound tracer resulting in
a better signal-to-noise ratio on the other hand. Investigations on
the metabolism revealed that IUdR tracers are rapidly degraded
and that the elimination of the deoxyribose residue leading to 5-
iodouracil (5-IU), and therewith to the loss of DNA integration
properties, is the rate-limiting process [7]. To circumvent this
obstacle a variety of IUdR analogues have been synthesized and
tested in vivo for their abilities as tumor tracing agents. Most
modifications to the IUdR structure were shown to be unsuitable
because metabolism turned out to be even faster, or the DNA
incorporation efficiency to be considerably poorer [8]. IUdR
derivatives modified with halogenations or methylations on the
deoxyribose residue did not accumulate in proliferating tissue any
longer [8]. An exchange of the ring oxygen atom in the
deoxyribose leading to 49-thio-29-deoxyuridine derivatives re-
vealed more promising results, yielding a high metabolic stability
and acceptable DNA incorporation rates. However, these
derivatives showed a reduced phosphorylation by thymidine
kinase 1 implicating an increased background radioactivity and,
furthermore, revealed a decreased cell uptake in different tumor
cell lines [8,9]. In conclusion, previous studies clearly demonstrate
strict limitations in varying the structure of IUdR to attain useful
new tumor tracing agents.
In the present study we produced two novel 39,59-diesterified
derivatives of IUdR with the aim to develop suitable tracers for
imaging cerebral tumors. Due to the higher lipophilicity of these
compounds and therewith an intended higher blood-brain barrier
permeability, we aimed to reach an increased uptake in brain
tissue. The radio nucleosides, 5-[125I]iodo-39,59-di-O-acetyl-29-
deoxyuridine (Ac2[
125I]IUdR) and 5-[125I]iodo-39,59-di-O-piva-
loyl-29-deoxyuridine (Piv2[
125I]IUdR) and their corresponding
alkylstannylated precursor molecules 5-tributylstannyl-39,59-di-O-
acteyl-29-deoxyuridine (Ac2Bu3SnUdR) and 5-tributylstannyl-
39,59-di-O-pivaloyl-29-deoxyuridine (Piv2Bu3SnUdR) were synthe-
sized and chemically characterized for the first time. To find out
whether Ac2[
125I]IUdR and Piv2[
125I]IUdR can be used as
imaging tracers, we first aimed at finding out if the novel
derivatives are stable in relation to enzymatic degradation and if
the tracers are integrated in the DNA of growing tumor cells. By in
vivo experiments in mice we wanted to investigate the biodistribu-
tion properties of each tracer and to measure the specific uptake in
brain tumor tissue. The overall aim was to find out if
diesterification of IUdR leads to beneficial properties for tracing
brain tumors.
Materials and Methods
Ethics Statement
All animal experiments were accomplished according to the EU
Council Directive 2010/63/EU and to the institutional guidelines
of Philipps-University Marburg and have been approved by the
responsible authority (Regierungspra¨sidium Gieben; permit num-
ber V54-19c 20 15(1) MR 20/15 Nr. 101/2011). Animals were
kept at 2361uC under standard 12 h light-dark cycle with free
access to food and water. The animals were sacrificed by a single
i.p. injection of 300 mg/kg pentobarbital. All surgery was
performed under ketamine-xylazine anesthesia, and all reasonable
measures were undertaken to prevent or to keep animal suffering
to a minimum.
General
Chemicals used for syntheses were obtained from Sigma Aldrich
(St. Louis, MO) and Alfa Aesar (Ward Hill, MA) in chemical
purities of $95%. Solvents applied in HPLC analyses were
purchased from Merck (Darmstadt, Germany), Acros Organics
(Geel, Belgium) and Sigma-Aldrich in gradient grade quality.
HPLC: All HPLC analyses were conducted on a 600E multi-
solvent delivery system connected with a photodiode array
detector 991 from Waters (Milford, MA). NMR: NMR spectra
were recorded on a JEOL-ECA 500 (500 MHz) NMR spectrom-
eter (Akishima, Tokyo, Japan). The values of the chemical shifts
are given in parts per million (ppm) and are related to the d- scale.
The solvent signal was used as internal reference.
Synthesis of 5-Iodo-39,59-di-O-acetyl-29-deoxyuridine
(Ac2IUdR)
5-iodo-29-deoxyuridine (1.50 g; 4.24 mmol) was dissolved in
30 mL pyridine and acetic anhydride (3.90 mL; 41.25 mmol) was
added slowly. The resulted mixture was stirred for 24 h at room
temperature, subsequently poured in 150 mL of cold 2 N HCl and
extracted with ethyl acetate. The organic layer was washed with
saturated NaHCO3 and NaCl aqueous solutions and dried
subsequently over anhydrous Na2SO4. After filtration and
evaporation of the solvent, the product, a white solid, was
recrystalized in ethanol yielding 1.66 g (90%). 1H NMR
(500 MHz, CDCl3) d 2.01 (s, 3H, CH200); 2.08 (m, 1H, CH29*);
2.10 (s, 3H, CH2-); 2.43 (m, 1H, CH29*); 4.19 (q, 1H, CH49);
4.23 (dd, 1H, CH59*); 4.30 (dd, 1H, CH59*); 5.23 (m, 1H, CH39);
6.28 (t, 1H, CH19); 7.96 (s, 1H, CH4); 8.35 (bs, 1H, NH). 13C
NMR (500 MHz, CDCl3) d 21.0 (C2-); 21.3 (C200); 38.5 (C29);
63.9 (C59); 68.9 (C5); 74.2 (C39); 82.9 (C19); 85.6 (C49); 143.9 (C6);
149.6 (C2); 159.4 (C4); 170.3 (C1-); 170.5 (C100).
Synthesis of 5-Iodo-39,59-di-O-pivaloyl-29-deoxyuridine
(Piv2IUdR)
5-iodo-29-deoxyuridine (1.50 g; 4.24 mmol) was dissolved in
30 mL pyridine and trimethylacetyl chloride (1.305 mL;
10.59 mmol) was added slowly at 0uC. The mixture was stirred
for 24 h at room temperature, subsequently poured in 120 mL ice
water and extracted 3 times with equal volumes of chloroform.
The unified organic layers were washed with 0.1 N HCl and the
solvent was evaporated. The residue was purified by preparative
HPLC (method A) to give 664 mg (30%) of a white solid as
product. 1H NMR (500 MHz, CDCl3) d 1.22 (s, 9H, CH3-); 1.26
(s, 9H, CH300); 2.09 (m, 1H, CH29*); 2.57 (m, 1H, CH29*); 4.25
(m, 1H, CH49); 4.31 (dd, 1H, CH59*); 4.53 (dd, 1H, CH59*); 5.18
(m, 1H, CH39); 6.21 (m, 1H, CH19); 7.88 (s, 1H, CH4); 8.26
(bs,1H, NH). 13C NMR (500 MHz, CDCl3) d 27.1 (C2-); 27.6
(C200); 38.5 (C29); 38.8 (C3-); 39.0 (C300); 64.0 (C59); 68.9 (C5);
74.1 (C39); 83.4 (C19); 85.7 (C49); 143.5 (C6); 149.5 (C2); 159.5
(C4); 178.1 (C1-); 178.2 (C100).
Synthesis of 5-Tributylstannyl-29-deoxyuridine
(Bu3SnUdR)
5-iodo-29-deoxyuridine (0.50 g; 1.41 mmol) was dissolved in
20 mL 1,4-dioxane and dichlorbis(triphenylphosphine)palladiu-
m(II) (25 mg; 0.04 mmol) and hexa-n-butylditin (1.54 g;
3.55 mmol) were added. The mixture was heated at 120uC for
5 h under a stream of nitrogen. After cooling the mixture was
filtrated and the solvent was removed by rotary evaporation. The
resulted residue was separated by preparative HPLC (method A)
to give 180.3 mg (25%) of the pure product; a thick, yellow
opalescent oil. 1H NMR (500 MHz, DMSO-d6) d 0.82 (t, 9H,
CH40); 0.94 (m, 6H, CH10); 1.24 (sex, 6H, CH30); 1.44(m, 6H,
CH20); 2.06 (m, 2H, CH29*); 3.50 (t, 2H, CH59*); 3.76 (q, 1H,
CH49); 4.20 (m, 1H, CH39); 4.88 (t, 1H, OH59); 5.19 (d, 1H,
OH39); 6.15 (t, 1H, CH19); 7.51 (t, 1H, CH4); 11.04 (s, 1H, NH);
Diesterified IUdR for Tracing Cerebral Tumors
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13C NMR (500 MHz, DMSO-d6) d 9.9 (C10); 14.1 (C40); 27.1
(C30); 29.0 (C20); 40.4 (C29); 62.1 (C59); 71.3 (C39); 84.7 (C19);
88.0 (C49); 111.5 (C5); 144.9 (C6); 151.4 (C2); 166.1 (C4).
Synthesis of 5-Tributylstannyl-39,59-di-O-acteyl-29-
deoxyuridine (Ac2Bu3SnUdR)
5-iodo-39,59-di-O-acetyl-29-deoxyuridine (1.00 g; 2.28 mmol)
was dissolved in 40 mL 1,4-dioxane and hexa-n-butylditin
(3.2 mL, 6.2 mmol) and dichlorbis(tri-phenylphosphine)-palladiu-
m(II) (40 mg; 0.06 mmol) were added. The mixture was heated at
120uC for 5 h under a stream of nitrogen. After cooling, the
solvent was removed by rotary evaporation. The resulted residue
was separated by preparative HPLC (method A) to give 451 mg
(33%) of the product; a yellowish oil. 1H NMR (500 MHz,
CDCl3) d 0.88 (t, 9H, CH40); 0.95–1.11 (m, 6H, CH10); 1.25–1.39
(m, 6H, CH30); 1.41–1,55 (m, 6H, CH20); 2.09 (s, 3H, CH200);
2.11 (s, 3H, CH2-); 2.18 (m, 1H, CH29*); 2.48 (m, 1H, CH29*);
4.24 (m,1H,CH49); 4.28 (dd, 1H, CH59*); 4.34 (dd, 1H, CH59*);
5.21 (m, 1H, CH39); 6.24 (m, 1H, CH19); 7.18 (t, 1H CH4); 8.16
(bs, 1H, NH). 13C NMR (500 MHz, CDCl3) d 10.0 (C10); 13.8
(C40); 20.9 (C2-); 21.0 (C200); 27.3 (C30); 29.0 (C20); 37.6 (C29);
63.9 (C59); 74.3 (C39); 82.2 (C19); 85.5 (C49); 113.5 (C5); 142.6
(C6); 150.7 (C2); 165.8 (C4); 170.3 (C1-); 170.4 (C100).
Synthesis of 5-Tributylstannyl-39,59-di-O-pivaloyl-29-
deoxyuridine (Piv2Bu3SnUdR)
5-iodo-39,59-di-O-pivaloyl-29-deoxyuridine (0.60 g; 0.88 mmol)
was dissolved in 20 mL 1,4-dioxane and hexa-n-butylditin
(1.3 mL, 2.5 mmol) and dichlorbis-(triphenylphosphine)-palladiu-
m(II) (20 mg; 0.03 mmol) were added. The mixture was heated at
120uC for 5 h under a stream of nitrogen. After cooling, the
solvent was removed by rotary evaporation. The resulted residue
was separated by preparative HPLC (method A) to give 216 mg
(36%) of the pure product; a slightly yellow, amorphous solid. 1H
NMR (500 MHz, CDCl3) d 0.88 (t, 9H, CH40); 0.96–1,11 (m, 6H,
CH10); 1.22 (s, 9H, CH200); 1.27–1.37 (m, 6H, CH30); 1.41–1.55
(m, 6H, CH20); 1.99 (s, 9H, CH300); 2.17 (m, 1H, CH29*); 2.52
(m, 1H, CH29*); 4.21 (m, 1H, CH49); 4.24 (dd, 1H, CH59*); 4.36
(dd, 1H, CH59*); 5.18 (m, 1H, CH39); 6.16 (m, 1H, CH19); 7.21 (t,
1H, CH4); 8.17 (bs, 1H, NH). 13C NMR (500 MHz, CDCl3) d
10.0 (C10); 13.8 (C40); 27.1 (C2-); 27.3 (C30); 27.6 (C200); 29.0
(C20); 37.8 (C29); 38.7 (C3-); 38.9 (C300); 63.9 (C59); 74.1 (C39);
82.5 (C19); 85.7 (C49); 113.1 (C5); 142.5 (C6); 150.6 (C2); 165.9
(C4); 178.0 (C100); 177.9 (C1-).
HPLC
Method A. The reaction product was dissolved in eluent
(dichlormethane-isopropanol, 90:10, v/v) at a maximum concen-
tration of 200 mg/mL. 1 mL was subjected to a preparative
column containing a SiOH normal phase (Nucleodur VarioPrep,
5 mm, ID 21 mm, L 250 mm Macherey-Nagel, Du¨ren, Germany).
An isocratic elution was carried out at a flow rate of 20 mL/min
over 20 min.
Method B. The residue was dissolved in 100 mL eluent
(acetonitrile-water, 90:10, v/v) and 50 mL were subjected to an
aminopropyl-modified normal phase (Nucleodur NH2, 5 mm, ID
4 mm, L 250 mm; Macherey-Nagel) carrying out an isocratic
elution at a flow rate of 0.5 mL/min over 15–20 min.
Method C. The evaporated samples were dissolved in 40 mL
eluent (acetonitrile-water, 80:20, v/v) and 20 ml were subjected to
an ammonium-sulfonic acid modified phase (Nucleodur Hilic,
5 mm, ID 4 mm, L 250 mm; Macherey-Nagel) with isocratic
elution conditions at a flow rate of 1.2 mL/min over 5 min.
Stability of the N-glycosidic Bond
The stability of the N-glycosidic bond was determined by in vitro
incubation of the cold tracers with human recombinant thymidine
phosphorylase (TP). Each iodonucleoside (IUdR, Ac2IUdR,
Piv2IUdR) was dissolved in 150 mM K2HPO4 buffer solution
(pH=7.4) at a concentration of 0.67 nmol/mL. 150 mL of this
solution were incubated with 0.5 mL TP solution (equal to 0.525
units, Sigma-Aldrich) for 0.5 and 6 h at room temperature (n = 4).
After incubation, the reaction solution was heated at 90uC for
5 min, filtered and extracted 3 times with 200 mL ethyl acetate.
The combined organic phases were evaporated and the residue
was dissolved in eluent (acetonitrile/water; 80:20) and submitted
to HPLC analysis (Method C). The resulting metabolite 5-
Iodouracil (5-IU) and intact tracers were quantitatively determined
and correlated to untreated controls.
Radiolabeling
The radiolabeling was carried out by using the method of
Toyohara et al. 2002 [9] with modifications. In short, 0.7 mL
water and 0.7 mL chloroform were poured into a reaction vial,
5 mL of a Na[125I]I (28 MBq in 0.1 N NaOH; Hartmann Analytic
GmbH, Braunschweig, Germany) and 5 mL of a freshly prepared
iodine solution (0.05 M, in chloroform) were added. After 10 s of
vortexing, the aqueous phase was removed and 100 mL of the
tracer precursor solution (Bu3SnUdR, Ac2Bu3SnUdR or Piv2-
Bu3SnUdR each dissolved in ethyl acetate at a concentration of
1.9 mM) were added. The mixture was vortexed for 10 s and
allowed to react for 20 h. After evaporation of the solvent, the
residue was dissolved in eluent and subjected to HPLC (method
B). The amount of radiolabeled nucleoside was determined by
peak area analysis referred to peaks of a serial dilution of cold
tracer. The labeling yield was 47% for [125I]IUdR, 39% for
Ac2[
125I]IUdR and 31% for Piv2[125I]IUdR with chemical
purities of .99%. Specific activities were adjusted to 50 MBq/
mmol.
Cell Lines
Murine glioma cells (GL261 [10,11]; provided by Prof. A.
Pagenstecher, Philipps-University, Marburg, Germany) and glio-
ma cells of the rat (CRL2397; from American Type Culture
Collection, Manassas, VA) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma-Aldrich), supplemented with
10% (v/v) fetal calf serum (FCS; Sigma-Aldrich) and 1% (v/v)
penicillin/streptomycin solution (PAA Laboratories Inc., Westbor-
ough, MA). Pheochromocytoma cells of the rat (PC12; provided
by Prof. C. Mo¨ller, Philipps-University, Marburg, Germany) were
cultured in DMEM, supplemented with 10% horse serum (Life
Technologies, Carlsbad, CA), 5% FCS and 1% (v/v) penicillin/
streptomycin solution.
For growth analysis, cells were seeded in 600 mm dishes
(Cellstar, Greiner Bio-One GmbH, Frickenhausen, Germany) at
26105 cells per dish in appropriate culture medium in triplicates.
The cells were trypsinized each day on 5 consecutive days and
counted using a counting cell chamber (Neubauer, Brand,
Wertheim, Germany). The doubling times (DTs) were determined
to be 17 h for CRL2397, 21 h for GL261 cells and 51 h for PC12
cells, respectively.
DNA Incorporation
The DNA incorporation of each tracer was determined by using
a quantitative extraction technique to separate small molecules,
RNA, DNA and proteins as described before [9,12]. For detailed
description see supporting information (protocol S1).
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Relative Biodistribution
Wildtype C57BL/6 mice (Charles River GmbH, Sulzfeld,
Germany), 9–11 weeks of age, were used for the experiments.
Mice (n = 6 per tracer) were injected intraperitoneally (i.p.) with
0.5 MBq of 125I-labeled tracer dissolved in 0.1 mL of 0.9% NaCl
solution and sacrificed 24 h later. After extensive transcardial
perfusion with ice-cold 0.9% NaCl solution, the organs were
dissected, weighed and their radioactivities were measured by a
gamma counter (Cobra II, Perkin-Elmer Packard, Waltham, MA).
Tumor-specific Uptake in vivo
Host wildtype C57BL/6 mice, 12–14 weeks of age were
anesthetized with ketamine-xylazine (87 and 13 mg/kg, respec-
tively), and fixed in a stereotaxic frame (Kopf Instruments,
Tujunga, CA). A burr hole was drilled in the skull and GL261
cells were aspirated using 27-gauge needle attached to a 10 mL
Hamilton syringe mounted in a manually driven micro injector
(Kd Scientific, Holliston, MA). Each animal received 6 mL of
DMEM, containing a suspension of 25.000 cells/mL, injected at a
flow rate of 0.5 mL/min into the striatum (from bregma: anterior
0.0 mm, lateral 3.0 mm, ventral 5.0 mm, incisor bar 0, according
to Franklin and Paxinos [13]). After 4 weeks, mice were injected
i.p. with 1 MBq of 125I-labeled tracer (n = 3 mice per tracer) and
sacrificed 24 h later. Animals were transcardially perfused with
ice-cold 0.9% NaCl solution and brains were dissected. From each
brain hemisphere, tumor-bearing and tumor-free side, defined
pieces of tissue (tumoral and non-tumoral) were cut-out, weighed
and their radioactivities were measured by a gamma counter
(Cobra II).
Results
Synthesis and Radiolabelling
Fig. 1 illustrates the synthesis routes of the radiolabeled
nucleosides. Both hydroxyl groups of commercially available
IUdR were esterified to give the diacetyl (Ac2IUdR) or dipivaloyl
(Piv2IUdR) derivatives [14,15]. In a so-called Stille reaction the
substances were subsequently alkylstannylated with hexa-n-butyl-
ditin in the presence of a palladium (II) catalyst to give the
corresponding tracer precursors (Bu3SnUdR, Ac2Bu3SnUdR and
Piv2Bu3SnUdR). Due to their high lipophilicity and therewith
sparse solubility in aqueous systems, iodination with conventional
labeling methods e.g. chloramine T or H2O2-HCl were not useful
or yielded too less radiolabeled product. Hence, a modified
method of Toyohara et al. was used [9], wherein Na125I was first
activated with iodine in a biphasic system of chloroform and
water. After removal of the aqueous phase, the lipophilic
iodonucleoside precursors, dissolved in ethyl acetate, could easily
be added and reacted to the radiolabeled tracers (Ac2[
125I]IUdR,
Piv2[
125I]IUdR and [125I]IUdR) with high specific activities
ranging between 57 and 125 MBq/mmol.
HPLC Separation
In order to separate the radiolabeled tracers from the unreacted
precursor molecules and therewith to receive the tracers chemi-
cally pure, we tested different HPLC columns and conditions. We
established a fast and straightforward HPLC method using a NH2
normal phase, facilitating to conduct the separation with a
relatively low concentration of water and without addition of acid
to the eluent (method B). For the sensitive esterified tracers, this
approach guaranteed mild and gentle conditions during the HPLC
process. By quantification of the peak areas and correlating them
with standard concentrations, the amounts and the specific
activities of produced radiolabeled tracers could be determined
very precisely (Fig. 2).
Susceptibility to N-glycosidic Bond Cleavage
Nucleoside tracers such as IUdR are highly susceptible to N-
glycosidic bond cleavage by the enzyme thymidine phosphorylase.
The cleavage leads to the metabolite 5-iodouracil and therewith to
the loss of the DNA integrating abilities of the tumor tracer. In
view of this, we investigated the stability of the synthesized tracers
against thymidine phosphorylase in vitro (Table 1). In short (0.5 h)
and long term (6 h) incubation conditions, the novel diesterified
tracers were nearly resistant to N-glycosidic bond cleavage. Almost
100% of both diesterified tracer was still intact after 6 h of
incubation, whereas the control IUdR was degraded completely.
Figure 1. Synthetic pathway of the nucleoside tracers. (A) 5-Iodo-29-deoxyuridine (IUdR) is esterified on both hydroxyl groups of the
deoxyribose. (B) The diesterified derivatives are trialkystannylated at position 5 of the uracil ring. (C) The tributyltannyl group is selectively exchanged
by iodine-125 (radioiodination).
doi:10.1371/journal.pone.0102397.g001
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DNA Incorporation
To determine whether the synthesized tracers are integrated in
DNA, we performed in vitro incubation experiments with brain
tumor and pheochromocytoma cells. Fig. 3 shows the time-
dependent DNA incorporation of the synthesized tracers
Ac2[
125I]IUdR and Piv2[
125I]IUdR compared to the control
[125I]IUdR in fast-growing glioma cells of the rat (CRL2397; DT
17 h) and mouse (GL261; DT 21 h), and in moderate-growing
pheochromocytoma cells of the rat (PC12; DT 51 h). The DNA
incorporation of each tracer followed an almost exponential like
curve when plotted over incubation time. Both synthesized tracers
were well integrated in DNA but did not reach the extent of the
control tracer [125I]IUdR within the 6 h observation period. In
comparison to [125I]IUdR, the DNA incorporation curves of
either diesterified tracer steepened (passed approx. 10% of the 6 h
uptake value) after a lag phase (beyond 1 h) probably resulting
from the ester cleavage activation step the tracers had to undergo
before being integrated in DNA. In the RNA, small molecules and
protein fractions, the tracers were only measurable on a baseline
level, except for Piv2[
125I]IUdR which had entered the small
molecule fraction of CRL2397 cells already at the first time point
(15 min) but persisted there to declining degree.
Relative Organ Distribution
To investigate the distribution behavior and the stability in vivo,
we applied the 125I-labeled tracers to healthy mice and measured
the radioactivities in different body organs after 24 h of exposure
(Table 2). Overall, Ac2[
125I]IUdR and Piv2[
125I]IUdR were
similarly distributed as the control [125I]IUdR, but especially
Ac2[
125I]IUdR showed some interesting differences. In
Ac2[
125I]IUdR injected animals we detected decreased amounts
of radioactivities in critical organs such as spleen and femur
(hematopoietic tissue), stomach, intestine and lung. This uptake
profile promises advantageous dosimetry in humans. In addition,
the lower uptake of Ac2[
125I]IUdR in the thyroid can be due to an
enhanced in vivo stability towards deiodination. In comparison to
[125I]IUdR, both diesterified tracers showed a slightly higher
accumulation in the brain correlating with the grade of
lipophilicity.
Uptake into Cerebral Tumors
Next, we wanted to evaluate the specific uptake of the
diesterified tracers in tumor tissue in vivo. Therefore we implanted
murine glioma cells (GL261) into one brain hemisphere of mice.
After 4 weeks of tumor growth, we measured the uptake of each
tumor tracer in the tissue of the tumor-bearing compared to
tumor-free hemisphere (Table 3). Ac2[
125I]IUdR and Pi-
v2[
125I]IUdR as well as the control tracer [125I]IUdR showed a
specific affinity for the tumor-bearing side. Ac2[
125I]IUdR
revealed the highest amount of tracer in the tumor-bearing
hemisphere. By comparing the ratios of tumor-bearing to tumor-
free side, the amount of Ac2[
125I]IUdR was nearly 68 times higher
in the tumor-bearing side, whereas for the control tracer
[125I]IUdR this ratio was only 51. This result may be an indication
Figure 2. HPLC separation on an aminopropyl-modified normal phase. Merged HPLC chromatograms of each precursor and its
corresponding iodine-125 labeled tracer (HPLC method B).
doi:10.1371/journal.pone.0102397.g002
Table 1. Susceptibility to N-glycosidic bond cleavage by thymidine phosphorylase after 0.5 and 6 h (n = 4) of incubation.
0.5 h 6 h
Tested nucleoside Formed 5-Iodo-uracil [%] Intact nucleoside [%] Formed 5-Iodo uracil [%] Intact nucleoside [%]
IUdR 100.9563.92 ,0.05* 99.2861.42 ,0.05*
Ac2IUdR 0.2860.00 99.3264.49 0.5060.12 98.7261.88
Piv2IUdR 0.0760.00 100.1862.05 0.2360.08 99.9063.50
values are given as percentage related to the amount of incubated iodonucleoside (mean 6 SEM).
*experimentally determined detection minimum of the HPLC system.
doi:10.1371/journal.pone.0102397.t001
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of a higher specific uptake of the Ac2[
125I]IUdR into cerebral
tumor tissue.
Discussion
Previous studies identified three important aspects that need to
be considered for the development of novel cerebral tumor tracers
based on the IUdR structure. First, the two hydroxyl groups of the
deoxyribosyl group in the IUdR structure are obligatory to ensure
the integration in DNA, second, an iodination of the uracil ring at
positions other than position 5 causes instability and third,
modifications at the deoxyribosyl group e.g. halogenation decrease
the efficiency of DNA integration [8,9,16,17]. These limitations
only allow minor structural modifications.
Figure 3. Time-dependent in vitro DNA incorporation of Ac2[
125I]IUdR and Piv2[
125I]IUdR compared to [125I]IUdR (control). The
amount of each tracer was determined in the RNA, DNA, small molecule and protein fraction after incubation (for 0.25, 0.5, 1, 3 and 6 h) in 3 different
tumor cell lines; (A) in glioma cells of the rat (CRL2397), (B) murine glioma cells (GL261) and (C) rat pheochromocytoma cells (PC12). The percentage
of incubation dose was related to total protein. Values are presented as mean 6 SEM (n= 3).
doi:10.1371/journal.pone.0102397.g003
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In the present work, we synthesized IUdR tracers with two
esterified hydroxyl groups of the deoxyribose ring. Therefore, we
first produced the diacetyl (Ac2IUdR) and dipivaloyl (Piv2IUdR)
derivatives which were then trialkylstannylated in position 5 of the
uracil ring to give the tracer precursors Ac2Bu3SnUdR and
Piv2Bu3SnUdR. The alkylstannylation was necessary to guarantee
the radiolabeling with iodine at this position. Additionally, it offers
the chance to produce the radiolabeled tracers in a one-pot
synthesis without further purification for in vivo application, since
the tributylstannyl group, which is cleaved during the radio-
synthesis, has a relatively low toxicity [18].
The tracer precursors were radiolabeled with iodine-125 which
was produced by Na125I and iodine in a biphasic system of
chloroform and water. This method, which has been described
previously [9], was best suited for labeling the lipophilic
precursors. By changing certain parameters, e.g. decreasing the
amount of water and chloroform or prolonging the reaction time,
we received higher labeling yields. Due to the longer reaction time
it was not necessary to stop the reaction by adding sodium
metabisulfite solution, thus the tracers were not additionally
adulterated with salts.
Metabolic stability is an important issue in the development of
new tumor tracers. For tracers based on IUdR the presence of the
enzyme thymidine phosphorylase (TP) is pivotal because it rapidly
cleaves the N-glycosidic bond which leads to tracer inactivation
[19]. This circumstance gets worsened by the fact that TP is not
only a ubiquitous enzyme but also occurs on upregulated levels in
solid tumors and is associated with tumor aggressiveness [20]. By
incubation experiments with TP under short and long term
conditions we found that both diesterified tracers revealed a high
stability of the N-glycosidic bond as compared to the control
IUdR. Nearly 100% of intact tracer was still measurable after 6 h
whereas IUdR was completely degraded within this time. In direct
comparison of the diesterified tracers, the dipivaloyl ester
(Piv2IUdR) showed a slightly higher resistance to TP than
Ac2IUdR. From this finding can be concluded that big space-
consuming ester groups on the deoxyribose residue sterically shield
the C-N bond against enzymatic cleavage, and this effect seems to
correlate with the size of the ester group.
Both tracers, Ac2[
125I]IUdR and Piv2[
125I]IUdR were specif-
ically integrated into the DNA of 2 glioma cell lines and PC12 cells
in vitro. Over time, DNA integration followed an almost
exponential like pattern whereas the levels of integrated
Ac2[
125I]IUdR and Piv2[
125I]IUdR were lower compared to the
control tracer [125I]IUdR. An explanation for this result might be
the activation step which the diesterified tracers must undergo
before they can be integrated in DNA, namely the enzymatic
hydrolysis of the esters. The activation step may also be the reason
for a higher lag time of the DNA integration curves of the
esterified tracers as compared to the control tracer [125I]IUdR.
By investigating the relative biodistribution of Ac2[
125I]IUdR or
Piv2[
125I]IUdR in mice, we found a mostly similar distribution
pattern as for the control [125I]IUdR. Interestingly, for
Ac2[
125I]IUdR, but not for Piv2[
125I]IUdR, we measured inten-
sively decreased amounts of tracer in the stomach and thyroid as
compared to the control [125I]IUdR. This result implies a higher in
Table 2. Relative radioactivity distribution of iodonucleosides 24 h after i.p. injection in healthy C57BL/6 Mice (n = 6 for each
tracer).
Organ [125I]IUdR Ac2[
125I]IUdR Piv2[
125I]IUdR
Blood 3.9661.06 4.1562.77 3.9060.93
Kidney 1.7160.37 1.7160.59 1.8460.43
Spleen 4.6060.54 3.4860.64 2.8160.59
Femur 2.9860.49 2.0660.38 2.4960.64
Thyroid 17.2464.23 7.4963.09 21.8767.69
Intestine 10.2761.13 6.6460.95 10.7762.52
Stomach 30.1068.58 14.2164.27 37.15610.09
Liver 1.1760.15 1.1260.38 1.2160.30
Heart 0.4660.07 0.4160.17 0.5060.13
Brain 0.0560.01 0.0660.03 0.0860.02
Muscle 0.5460.12 0.7760.52 0.5660.11
Lung 1.4460.45 0.8660.17 2.1761.02
values are given in percentage of injected dose per gram61021 (mean 6 SEM).
doi:10.1371/journal.pone.0102397.t002
Table 3. Uptake of iodonucleosides in tumor tissue in vivo (n = 3 for each tracer).
Iodonucleoside Tumor-bearing hemisphere* Tumor-free hemisphere*
Ratio tumor-bearing/tumor-free
hemisphere
[125I]IUdR 4.4561.41 0.0960. 05 51
Ac2[
125I]IUdR 11.1664.36 0.1760.04 68
Piv2[
125I]IUdR 1.0760.27 0.1860.05 6
*values are given in percentage of injected dose per gram61023 (mean 6 SEM).
doi:10.1371/journal.pone.0102397.t003
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vivo stability. Furthermore, the organ distribution of
Ac2[
125I]IUdR pointed to a lower whole body dose exposition.
The amount of Ac2[
125I]IUdR and Piv2[
125I]IUdR were increased
within the brains compared to animals which received [125I]IUdR.
Although this result was not statistically significant, nevertheless, it
suggests that lipophilic diesterified IUdR tracers enter the brain to
a greater extent than the hydrophilic IUdR. Interestingly,
lipophilic 59-monoesterified IUdR derivatives have already been
shown to be increasingly transported through the blood-brain-
barrier in a previous study [21].
Both diesterified tracers, Ac2[
125I]IUdR and Piv2[
125I]IUdR
revealed a specific uptake into the tumor-bearing brain side of
mice which have been grafted with glioma cells. Ac2[
125I]IUdR
showed the quantitatively highest accumulation in the tumor-
bearing side and showed a higher tumor-bearing to tumor-free
ratio as compared to the control tracer [125I]IUdR. This ratio was
much smaller for the more lipophilic Piv2[
125I]IUdR which
additionally showed a higher accumulation in the tumor-free side
as compared to the other tracers.
Taken together, in the present study we synthesized two novel
diesterified IUdR derivatives and tested their properties as tumor
tracers in in vitro and in vivo experiments. Our results show that
diesterification highly protects IUdR-tracers from metabolic
degradation. Furthermore, the chemical modification led to
higher amounts of diesterified tracers in healthy mice brains. We
saw a specific accumulation of one diesterified tracer (Ac2IUdR) in
the tumor bearing side of mice grafted unilaterally with brain
tumor cells, whereas the specificity seems not only to be related to
the fact of diesterification but also to the type of ester residue. The
diesterified IUdR tracers were specifically integrated in DNA in
vitro, although to a lower level than the control IUdR. The latter
result raises the questions of how good the diesterified IUdR
tracers are integrated in DNA in vivo and how suitable they are for
labeling brain tumors in imaging analysis. These issues need to be
addressed in further investigations.
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